Metrics as of 10/16/2026, 07:03 AM (Berlin time), refresh in progress.
Sana Biotechnology Stock
Sana Biotechnology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Steven D. Harr
- Employees
- 142
- Market cap
- $741 M
- IPO
- 04/02/2021
- Web
- www.sana.com
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system…
Sana Biotechnology stock: price history
1D
+6.4%
1W
-11.1%
1M
-21.5%
6M
-28.5%
YTD
-39.1%
1Y
-58.1%
2Y
-40.1%
5Y
-88.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~19% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Sana Biotechnology
Analyst assessment of Sana Biotechnology
PRICE TARGET LOW
US$7.00
CONSENSUS
US$8.50
MEDIAN
US$7.50
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
9
BUY
2
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 14/08/2026
Sana Biotechnology stock metrics
P/E
-3.26
P/B
4.73
EV/EBITDA
-3.77
RETURN ON EQUITY
-41.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.48
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
62.4%
FLOAT SHARES
186,784,799
AVG. DAILY VOLUME (30D)
3,990,770
Insider transactions (SEC)
Bishop Hans Edgar
PATEL DHAVALKUMAR DHIRAJLAL
PATEL DHAVALKUMAR DHIRAJLAL
Bishop Hans Edgar
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +6.4%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Sana Biotechnology stock
What does Sana Biotechnology do?
Sana Biotechnology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Steven D. Harr, the company employs around 142 people.
The IPO was on 04/02/2021; the stock trades on NASDAQ under the ticker SANA.
What do analysts say about Sana Biotechnology stock?
11 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$8.50, ranging from US$7.00 to US$12.00, with a median of US$7.50.
This is an external assessment, not a statement by Market Jury.
When does Sana Biotechnology report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 19% stronger than usual.
Does Sana Biotechnology pay a dividend?
No, Sana Biotechnology currently does not pay a dividend.
Which stocks are comparable to Sana Biotechnology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Sana Biotechnology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sana Biotechnology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.